Literature DB >> 10499235

Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens.

U Knoll1, G Glünder, M Kietzmann.   

Abstract

The plasma pharmacokinetics of danofloxacin and enrofloxacin in broiler chickens was investigated following single intravenous (i.v.) or oral administration (p.o.) and the steady-state plasma and tissue concentrations of both drugs were investigated after continuous administration via the drinking water. The following dosages approved for the treatment of chickens were used: danofloxacin 5 mg/kg and enrofloxacin 10 mg/kg of body weight. Concentrations of danofloxacin and enrofloxacin including its metabolite ciprofloxacin were determined in plasma and eight tissues by specific and sensitive high performance liquid chromatography methods. Pharmacokinetic parameter values for both application routes calculated by noncompartmental methods were similar for danofloxacin compared to enrofloxacin with respect to elimination half-life (t1/2: approximately 6-7 h), mean residence time (MRT; 6-9 h) and mean absorption time (MAT; 1.44 vs. 1.20 h). However, values were twofold higher for body clearance (ClB; 24 vs. 10 mL/min. kg) and volume of distribution at steady state (VdSS; 10 vs. 4 L/kg). Maximum plasma concentration (Cmax) after oral administration was 0.5 and 1.9 micrograms/mL for danofloxacin and enrofloxacin, respectively, occurring at 1.5 h for both drugs. Bioavailability (F) was high: 99% for danofloxacin and 89% for enrofloxacin. Steady-state plasma concentrations (mean +/- SD) following administration via the drinking water were fourfold higher for enrofloxacin (0.52 +/- 0.16 microgram/mL) compared to danofloxacin (0.12 +/- 0.01 microgram/mL). The steady-state AUC0-24 h values of 12.48 and 2.88 micrograms.h/mL, respectively, derived from these plasma concentrations are comparable with corresponding area under the plasma concentration-time curve (AUC) values after single oral administration. For both drugs, tissue concentrations markedly exceeded plasma concentrations, e.g. in the target lung, tissue concentrations of 0.31 +/- 0.07 microgram/g for danofloxacin and 0.88 +/- 0.24 microgram/g for enrofloxacin were detected. Taking into account the similar in vitro activity of danofloxacin and enrofloxacin against important pathogens in chickens, a higher therapeutic efficacy of water medication for enrofloxacin compared to danofloxacin can be expected when given at the approved dosages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499235     DOI: 10.1046/j.1365-2885.1999.00217.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  14 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Residues of fluoroquinolones in marine aquaculture environment of the Pearl River Delta, South China.

Authors:  Xiuting He; Zhaohui Wang; Xiangping Nie; Yufen Yang; Debo Pan; Anna O W Leung; Zhang Cheng; Yongtao Yang; Kaibin Li; Kunci Chen
Journal:  Environ Geochem Health       Date:  2011-09-01       Impact factor: 4.609

3.  Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

Authors:  J A Schrickx; J Fink-Gremmels
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

4.  Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and female turkeys following intravenous and oral administration.

Authors:  D J Dimitrova; L D Lashev; St G Yanev; V T Pandova
Journal:  Vet Res Commun       Date:  2006-05       Impact factor: 2.459

5.  Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys.

Authors:  A M Haritova; N V Rusenova; P R Parvanov; L D Lashev; J Fink-Gremmels
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

6.  Effect of administration route and dose escalation on plasma and intestinal concentrations of enrofloxacin and ciprofloxacin in broiler chickens.

Authors:  Mathias Devreese; Gunther Antonissen; Siegrid De Baere; Patrick De Backer; Siska Croubels
Journal:  BMC Vet Res       Date:  2014-12-02       Impact factor: 2.741

7.  Evaluation of the Presence and Levels of Enrofloxacin, Ciprofloxacin, Sulfaquinoxaline and Oxytetracycline in Broiler Chickens after Drug Administration.

Authors:  Débora Cristina Sampaio de Assis; Guilherme Resende da Silva; Isabela Pereira Lanza; Ana Cláudia Dos Santos Rossi Ribeiro; Ângela Maria Quintão Lana; Leonardo José Camargos Lara; Tadeu Chaves de Figueiredo; Silvana de Vasconcelos Cançado
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

8.  Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.

Authors:  Nan Zhang; Xiaomei Ye; Yuzhi Wu; Zilong Huang; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

9.  Enrofloxacin Dose Optimization for the Treatment of Colibacillosis in Broiler Chickens Using a Drinking Behaviour Pharmacokinetic Model.

Authors:  Robin Temmerman; Ludovic Pelligand; Wim Schelstraete; Gunther Antonissen; An Garmyn; Mathias Devreese
Journal:  Antibiotics (Basel)       Date:  2021-05-19

10.  Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers.

Authors:  Mengjie Guo; Shamsuddin Bughio; Yong Sun; Yu Zhang; Lingling Dong; Xiaohua Dai; Liping Wang
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.